Axcynsis Therapeutics

We’re thrilled to welcome Professor Patricia LoRusso, D.O., to Axcynsis Therapeutics’ Scientific Advisory Board! A world-renowned leader in oncology and early-phase drug development, Prof. LoRusso brings invaluable expertise as we advance our innovative Antibody Drug Conjugates into clinical trials. “As Axcynsis transitions to the clinical stage, Prof. LoRusso’s strategic guidance will be pivotal,” said Dr. ZOU BIN, CEO of Axcynsis. Prof. LoRusso added, “Axcynsis’ pipeline portfolio holds tremendous potential, and I am excited to see it progress through the clinical pipeline.” We’re honored to have her on board as we strive to bring transformative therapies to patients. Read more: https://lnkd.in/g7UgYidr #OncologyInnovation #ScientificLeadership #LifeSciences

We are happy to announce that Axcynsis Therapeutics recently became one of 150 companies worldwide to earn a coveted presentation slot at the 16th annual New England Venture Summit, hosted by youngStartup Ventures. The Summit connects founders of the hottest venture backed, emerging and early-stage companies with an exclusive audience of venture capitalists, corporate investors, private investors, investment bankers, and strategic partners. Our CEO, Dr. ZOU BIN, will present at the event. For more info on the event visit https://lnkd.in/eitmsD7m #AxcynsisTherapeutics #ADC #innovation #startup #nevs24 #NewEnglandVentureSummit #youngstartupventures

Axcynsis Therapeutics is thrilled to welcome Cheni Kwok Ph.D. CLP. (郭珍仪) as our new Senior Business Development Advisor! Dr. Cheni Kwok is the Managing Partner & Founder of Linear Dreams LLC, a life sciences consultancy. Cheni has advised over 70 clients in a broad range of business and corporate development activities. She served as SVP of Corporate Development at Poniard Pharmaceuticals prior to founding Linear Dreams and held various business development roles at Celera, and Exelixis. She began her career in research and alliance management at GlaxoSmithKline. Chen holds a Ph.D. in Human Molecular Genetics from the University of Cambridge and a BSc in Biotechnology from Imperial College London. We look forward to the value she will bring to our BD efforts as we continue our journey in advancing therapeutic innovation! 💼✨ #BusinessDevelopment #LifeSciences #AxcynsisTherapeutics #WelcomeCheniKwok #CorporateStrategy #Pharma #Innovation

We're thrilled to have two talented interns join us this summer! Xubing, a Master's student in Applied Biomedicine at NUS, brings a wealth of research experience to our team (right in photo). Rachel, a second-year Chemistry student at NTU, is eager to learn and contribute in the lab environment (left in photo). Axcynsis is dedicated to fostering the next generation of Singaporean talent. Our internship program provides a valuable platform for curious and motivated students to develop their skills and flourish in their chosen fields. Want to be part of our team? We regularly post internship opportunities on university platforms or feel free to reach out to us directly as well! #AxcynsisTherapeutics #ADC #internship

Axcynsis Therapeutics is proud and honoured to share that we were awarded the second place in the recent Pitch Competition co-hosted by Boston Chinese Investment Club and HKSTP - Hong Kong Science and Technology Parks Corporation on 27th April 2024! Our team in USA were also thrilled to be able to participate in the event onsite at Boston! Read more: https://lnkd.in/gZ6zEcWB #Axcynsistherapeutics #Biotechnology #ADC

Axcynsis Therapeutics is proud to share that we are one of the 14 Finalists selected in this prestigious Annual Biomedical Pitch Competition 2024 organised by Boston Chinese Investment Club, BCIC. The selected finalists are high-quality teams, ranging from early-stage to mid-stage and from pharmaceutic to medical device and diagnostics.   One of Axcynsis’ pitch highlights includes our approach that seamlessly integrates advanced antibody discovery, AxcynCYS™ site-specific conjugation, and a proprietary payload, AxcynDOT™, with a novel mechanism of action.   Since 2022, Boston Chinese Investment Club has hosted Annual Biomedical Pitch Competitions, empowering start-ups to secure over $60 million in collective funding. The final pitch competition will be held both online and in-person in Boston on 27th April 2024. Stay tuned for further updates!   #BCIC #AxcynsisTherapeutics #ADC

Axcynsis Therapeutics will present three posters on their leading ADC assets at American Association for Cancer Research (AACR) Annual Meeting 2024. Our pioneering approach seamlessly integrates advanced antibody discovery, AxcynCYS™ site-specific conjugation, and a proprietary payload with a novel mechanism of action with the potential of overcoming drug resistance encountered with current ADC payloads like DM1, MMAE, and DXd.   The poster presentations will showcase our preclinical data including the in-vitro potency, in-vivo efficacy, and safety profile in rodents and non-human primates.   ZOU BIN, Bryan K.S. Yeung, Chen Zhong, Yinwen Cheng will be representing Axcynsis in the AACR 2024.   #AACR #AxcynsisTherapeutics #ADC

Axcynsis wishes everyone good health, success and prosperity in the year of Dragon! 恭贺新禧迎新春，携手同行创辉煌。值此龙年佳节, 祝大家在新的一年里身体健康、家庭和睦、事业有成。 #CNY2024 #AxcynsisTherapeutics #Biotechnology #ADC